[Liposomal-amphotericin B efficacy and safety].
Liposomal amphotericin B (L-AMB), a lipid-based amphotericin B formulation, has been used in Japan since June 2006 to treat fungal infection. In the 3 years since L-AMB was launched, few reports have been made on its status. To ensure its appropriate use, we restrospectively reviewed its efficacy and safety in treating fungal infections. 25 subjects with fungal infection treated with L-AMB from April 2007 until February 2008. Of those, 16 showed clinical improvement. Elevated serum creatinine occurred in 1 and decreased serum potassium in 6. We found a positive relationship between the serum potassium decrease and L-AMB dose. Logistic regression analysis of this relationship showed that serum potassium tended to fall on day 5 to 6 of L-AMB administration. While L-AMB appears highly effective in fungal infection, it requires serum potassium monitoring to ensure patient safety.
Hamada
Yukihiro
Y
Department of Pharmacy, Kitasato University Hospital.
Komatsu
Toshiaki
T
Seto
Yoshinori
Y
Matsubara
Hajime
H
Kume
Hikaru
H
Sunakawa
Keisuke
K
Yago
Kazuo
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D000935:Antifungal Agents; D008081:Liposomes; D000666:Amphotericin B